Our idea of using Casp1 as a therapeutic target is based on the identification of the Nlrp1-Casp1-Casp6 neuronal degeneration pathway in CNS primary human neurons, the association of this pathway with memory and cognitive impairment in aged humans and mice11–16,36,37, and the genetic association between NLRP1 and CASP1 with AD progression or AD38,39. Here, NLRP1 is linked to Cognitive impairment.